[Cancer procoagulant (CP)].
Epidemiological studies point out steady increase of the incidence of cancer disease in Poland and all over the world. Neoplasms are associated with blood coagulation disorders very frequently. The investigations concentrate on searching for the substance producing malignant cells and causing activation of blood coagulation in neoplasm disease patients. Gordon and co-workers were the first who published results of their investigation in searching for such a substance in 1975. It was isolated from the rabbit's neoplasm type V2 Ca and then characterized and named as cancer procoagulant (CP). Cancer procoagulant is responsible for blood coagulation disorders in neoplasm disease patients, incorrect metabolism of fibrin and its concentration around malignant tissues. This enzyme (in vitro) is a direct activator of the factor X, without contribution of factor VII or any other cofactors. CF differs in physical, chemical and enzymatic activity from others procoagulants. The main aim of the paper is a review of the literature for structure, chemical characteristic, occurrence and clinical relevance of the cancer procoagulant (CP) and its clinical use in current oncological diagnostics.